AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05933122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexologist consult
Description: in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life.
Study NCT05933122 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standart of care
Description: in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist
Study NCT05621798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Manufacturer's Software
Description: When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software.
Study NCT05621798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REM (Real Ear Measurements)
Description: Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
Study NCT06364150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell injection
Description: For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
Study NCT05869643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose STP0404 (Pirmitegravir)
Description: Once daily, oral capsule taken after breakfast
Study NCT05869643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose STP0404 (Pirmitegravir)
Description: Once daily, oral capsule taken after breakfast
Study NCT05869643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose STP0404 (Pirmitegravir)
Description: Once daily, oral capsule taken after breakfast
Study NCT05869643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule, taken orally once daily after breakfast
Study NCT05581160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
Description: Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C.
Study NCT05604391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft placed apically
Description: For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
Study NCT05604391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft placed coronally
Description: For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
Study NCT04478305 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duavive 0.45Mg-20Mg Tablet
Description: Duavee, marketed as Duavive in Canada.
Study NCT05560399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
Study NCT05560399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
Study NCT05560399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for > 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for > 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for
Study NCT06468657 — intervention group
Intervention type: OTHER
Intervention: mortality rates
Description: mortality rates
Study NCT06629012 — intervention group
Intervention type: PROCEDURE
Intervention: Breast reconstruction with neurotization
Description: Patients received breast reconstruction with neurotization procedure
Study NCT06629012 — intervention group
Intervention type: PROCEDURE
Intervention: Breast reconstruction without neurotization
Description: Patients received breast reconstruction without neurotization
Study NCT06630468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented occupational therapy (TOOT)
Description: The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
Study NCT04158635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT04158635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT04158635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04158635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06504173 — intervention group
Intervention type: PROCEDURE
Intervention: diced cartilage
Description: In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
Study NCT05820100 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel.
Study NCT05288634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise
Description: Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
Study NCT05034484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-303
Description: Multiple dose levels will be evaluated.
Study NCT05034484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study NCT06630468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
Study NCT06630507 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational module
Description: 1 hour pre-recorded educational module created by Dr. Sharma.
Study NCT06631703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group receiving Oral Colostrum Administiration
Description: Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
Study NCT06631625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Intravenous Infusion
Description: Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
Study NCT06631625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and ketamine
Description: Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
Study NCT06631625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and dexmedetomidine infusion
Description: Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
Study NCT06632132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial resistance Training in Hemodialysis Units
Description: The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos.
Study NCT05926505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
Study NCT05926505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Description: Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
Study NCT05741931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)
Description: The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
Study NCT05693883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
Study NCT05623839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC
Study NCT05623839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04970641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Good Things (3GT) Positive Psychology journaling activity
Description: Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
Study NCT05147584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual fetal oxygen sensors
Description: Placement of both internal and external fetal oxygen sensors
Study NCT05537896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Description: Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC >500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)
Study NCT05803473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)
Description: For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2.
Study NCT05803473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Precision Pro Glucometer for glucose POC testing
Description: For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
Study NCT05556226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154 Dose Formulation A
Description: Subcutaneous Injection
Study NCT05556226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154 Dose Formulation B
Description: Subcutaneous Injection
Study NCT05942300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
Study NCT05942300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
Study NCT05235750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation writing
Description: Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
Study NCT06292182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light
Description: daily application of near-infrared light
Study NCT05258006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous demineralized dentin nanoparticles
Description: Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
Study NCT05258006 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autogenous demineralized dentin nanoparticles
Description: Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
Study NCT05128903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA714
Description: Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy
Study NCT04906512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Tegaderm™ CHG I.V. Securement Dressing
Description: Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
Study NCT04906512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Tegaderm™ Transparent Film Dressing 1626W
Description: Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
Study NCT04955730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Negative Pressure Wound Therapy is a single use NPWT that produces a negative pressure at -80 mmHg. Participants will have their fascia and skin closed in the same manner as the control arm participants, and will wear the NPWT dressing for 7 days after surgery.
Study NCT06158490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061 15 mg
Description: Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
Study NCT06158490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0061 30 mg
Description: articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
Study NCT06158490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
Study NCT04934527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotect
Description: The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
Study NCT06008080 — intervention group
Intervention type: DEVICE
Intervention: Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System
Description: Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System